128 related articles for article (PubMed ID: 18048768)
1. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice.
van Wanrooij EJ; de Jager SC; van Es T; de Vos P; Birch HL; Owen DA; Watson RJ; Biessen EA; Chapman GA; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):251-7. PubMed ID: 18048768
[TBL] [Abstract][Full Text] [Related]
2. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo.
Veillard NR; Steffens S; Pelli G; Lu B; Kwak BR; Gerard C; Charo IF; Mach F
Circulation; 2005 Aug; 112(6):870-8. PubMed ID: 16061736
[TBL] [Abstract][Full Text] [Related]
3. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
van Wanrooij EJ; Happé H; Hauer AD; de Vos P; Imanishi T; Fujiwara H; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2642-7. PubMed ID: 16239591
[TBL] [Abstract][Full Text] [Related]
4. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells.
Heller EA; Liu E; Tager AM; Yuan Q; Lin AY; Ahluwalia N; Jones K; Koehn SL; Lok VM; Aikawa E; Moore KJ; Luster AD; Gerszten RE
Circulation; 2006 May; 113(19):2301-12. PubMed ID: 16682613
[TBL] [Abstract][Full Text] [Related]
5. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.
Zirlik A; Maier C; Gerdes N; MacFarlane L; Soosairajah J; Bavendiek U; Ahrens I; Ernst S; Bassler N; Missiou A; Patko Z; Aikawa M; Schönbeck U; Bode C; Libby P; Peter K
Circulation; 2007 Mar; 115(12):1571-80. PubMed ID: 17372166
[TBL] [Abstract][Full Text] [Related]
6. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development.
Luchtefeld M; Grothusen C; Gagalick A; Jagavelu K; Schuett H; Tietge UJ; Pabst O; Grote K; Drexler H; Förster R; Schieffer B
Circulation; 2010 Oct; 122(16):1621-8. PubMed ID: 20921438
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
8. Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis.
de Nooijer R; Bot I; von der Thüsen JH; Leeuwenburgh MA; Overkleeft HS; Kraaijeveld AO; Dorland R; van Santbrink PJ; van Heiningen SH; Westra MM; Kovanen PT; Jukema JW; van der Wall EE; van Berkel TJ; Shi GP; Biessen EA
Arterioscler Thromb Vasc Biol; 2009 Feb; 29(2):188-94. PubMed ID: 19095996
[TBL] [Abstract][Full Text] [Related]
9. Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis.
Preusch MR; Rattazzi M; Albrecht C; Merle U; Tuckermann J; Schütz G; Blessing E; Zoppellaro G; Pauletto P; Krempien R; Rosenfeld ME; Katus HA; Bea F
Arterioscler Thromb Vasc Biol; 2008 Dec; 28(12):2158-64. PubMed ID: 18787189
[TBL] [Abstract][Full Text] [Related]
10. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
[TBL] [Abstract][Full Text] [Related]
11. Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro.
Schapira K; Burkly LC; Zheng TS; Wu P; Groeneweg M; Rousch M; Kockx MM; Daemen MJ; Heeneman S
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2021-7. PubMed ID: 19762780
[TBL] [Abstract][Full Text] [Related]
12. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice.
Sun L; Ishida T; Yasuda T; Kojima Y; Honjo T; Yamamoto Y; Yamamoto H; Ishibashi S; Hirata K; Hayashi Y
Cardiovasc Res; 2009 May; 82(2):371-81. PubMed ID: 19176597
[TBL] [Abstract][Full Text] [Related]
13. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.
Shiraishi Y; Watanabe T; Suguro T; Nagashima M; Kato R; Hongo S; Itabe H; Miyazaki A; Hirano T; Adachi M
J Hypertens; 2008 Oct; 26(10):1955-65. PubMed ID: 18806619
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
15. P55 tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice.
Xanthoulea S; Gijbels MJ; van der Made I; Mujcic H; Thelen M; Vergouwe MN; Ambagts MH; Hofker MH; de Winther MP
Cardiovasc Res; 2008 Nov; 80(2):309-18. PubMed ID: 18628255
[TBL] [Abstract][Full Text] [Related]
16. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice.
Petrovan RJ; Kaplan CD; Reisfeld RA; Curtiss LK
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1095-100. PubMed ID: 17303776
[TBL] [Abstract][Full Text] [Related]
17. CCR5 and CXCR3 are dispensable for liver infiltration, but CCR5 protects against virus-induced T-cell-mediated hepatic steatosis.
Holst PJ; Orskov C; Qvortrup K; Christensen JP; Thomsen AR
J Virol; 2007 Sep; 81(18):10101-12. PubMed ID: 17626099
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.
Jopling LA; Watt GF; Fisher S; Birch H; Coggon S; Christie MI
Br J Pharmacol; 2007 Dec; 152(8):1260-71. PubMed ID: 17982480
[TBL] [Abstract][Full Text] [Related]
19. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes.
Kawada K; Hosogi H; Sonoshita M; Sakashita H; Manabe T; Shimahara Y; Sakai Y; Takabayashi A; Oshima M; Taketo MM
Oncogene; 2007 Jul; 26(32):4679-88. PubMed ID: 17297455
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
